The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
- PMID: 30501907
- DOI: 10.1016/j.blre.2018.11.003
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Abstract
Multiple myeloma, which ranks as the second most common hematological malignancy, is known for its great genetic heterogeneity. One pathway, however, stands out in this diverse group. NF-κB pathway is one of the most important pathways in multiple myeloma not only for its role in pathogenesis, but also for its importance in various treatment strategies. Mutations in several major components of the NF-κB pathway and its regulators are present in at least 17% of primary multiple myeloma tumors and 42% of multiple myeloma cell lines. The NF-κB pathway regulates numerous genes, which influence development and pathogenesis of multiple myeloma. This significance of NF-κB for myeloma cells, however, is used against them, as current treatment strategies often use NF-κB as their primary or secondary target.
Keywords: Bone marrow; Multiple myeloma; NF-κB; Proteasome inhibitor; Therapy.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.Leuk Lymphoma. 2019 Mar;60(3):772-781. doi: 10.1080/10428194.2018.1493727. Epub 2019 Jan 15. Leuk Lymphoma. 2019. PMID: 30644322
-
NF-κB dysregulation in multiple myeloma.Semin Cancer Biol. 2016 Aug;39:68-76. doi: 10.1016/j.semcancer.2016.08.005. Epub 2016 Aug 17. Semin Cancer Biol. 2016. PMID: 27544796 Review.
-
The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.J Clin Exp Hematop. 2016;56(1):20-7. doi: 10.3960/jslrt.56.20. J Clin Exp Hematop. 2016. PMID: 27334854 Free PMC article. Review.
-
Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro.Leuk Res. 2012 Apr;36(4):514-20. doi: 10.1016/j.leukres.2011.11.014. Epub 2012 Jan 4. Leuk Res. 2012. PMID: 22226224
-
Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.Cardiovasc Hematol Disord Drug Targets. 2013 Mar 1;13(1):16-34. doi: 10.2174/1871529x11313010003. Cardiovasc Hematol Disord Drug Targets. 2013. PMID: 23534949 Review.
Cited by
-
NF-kB's contribution to B cell fate decisions.Front Immunol. 2023 Jul 18;14:1214095. doi: 10.3389/fimmu.2023.1214095. eCollection 2023. Front Immunol. 2023. PMID: 37533858 Free PMC article. Review.
-
Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis.Cell Cycle. 2020 Dec;19(23):3289-3302. doi: 10.1080/15384101.2020.1839701. Epub 2020 Nov 1. Cell Cycle. 2020. PMID: 33131409 Free PMC article.
-
ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma.EJHaem. 2024 Jun 5;5(4):677-689. doi: 10.1002/jha2.903. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157602 Free PMC article.
-
Analysis of genomic alterations in primary central nervous system lymphoma.Medicine (Baltimore). 2023 Sep 1;102(35):e34931. doi: 10.1097/MD.0000000000034931. Medicine (Baltimore). 2023. PMID: 37657032 Free PMC article.
-
Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation.Cells. 2021 Sep 2;10(9):2287. doi: 10.3390/cells10092287. Cells. 2021. PMID: 34571936 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical